4.5 Article

Depression and risk of transformation of episodic to chronic migraine

Journal

JOURNAL OF HEADACHE AND PAIN
Volume 13, Issue 8, Pages 615-624

Publisher

BMC
DOI: 10.1007/s10194-012-0479-9

Keywords

Depression; Chronic migraine; Epidemiology; Transformation; Migraine; Risk factors

Funding

  1. Ortho-McNeil Neurologics, Inc., Titusville, NJ
  2. Allergan Inc., Irvine, CA
  3. Advanced Bionics
  4. Allergan Pharmaceuticals
  5. Endo Pharmaceuticals
  6. GlaxoSmithKline
  7. Minster
  8. Merck, Inc.
  9. Neuralieve
  10. Novartis
  11. OrthoMcNeil
  12. Pfizer
  13. ProEthics/KOWA
  14. National Headache Foundation
  15. National Institute of Health
  16. GSK
  17. ENDO
  18. Allergan
  19. MSD
  20. Iroko Pharmaceuticals
  21. MAP Pharmaceuticals

Ask authors/readers for more resources

The aim of this study was to assess the role of depression as a predictor of new onset of chronic migraine (CM) among persons with episodic migraine (EM). The American Migraine Prevalence and Prevention (AMPP) study followed 24,000 persons with severe headache identified in 2004. Using random-effects logistic regression, we modeled the probability that persons with EM in 2005 or 2006 would develop CM in the subsequent year. Depression was assessed in two ways, using a validated questionnaire (PHQ-9 score a parts per thousand yen15) and based on self-reported medical diagnosis. Analyses were adjusted for multiple covariates including sociodemographics, body mass index, headache pain intensity, headache frequency, migraine symptom severity, cutaneous allodynia, acute medication overuse, anti-depressant use and anxiety. Of 6,657 participants with EM in 2005, 160 (2.4 %) developed CM in 2006. Of 6,852 participants with EM in 2006, 144 (2.2 %) developed CM in 2007. In fully adjusted models, PHQ-9 defined depression was a significant predictor of CM onset [odds ratio (OR) = 1.65, 95 % CI 1.12-2.45]. There was a depression-dose effect; relative to participants with no depression or mild depression, those with moderate (OR = 1.77, 95 % CI 1.25-2.52), moderately severe (OR = 2.35, 95 % CI 1.53-3.62), and severe depression (OR = 2.53, 95 % CI 1.52-4.21) were at increased risk for the onset of CM. Among persons with EM, depression was associated with an increased risk of CM after adjusting for sociodemographic variables and headache characteristics. Depression preceded the onset of CM and risk increased with depression severity suggesting a potentially causal role though reverse causality cannot be excluded.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available